Novartis shares tumble after del-desiran trial fails, worst day in 20+ years
Novartis (NVS) shares slid 14% after a late-stage study of del-desiran in myotonic dystrophy type 1 failed its primary test, the second failed trial in a week.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.